Drug Trial Radar · NCT04040634
Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,476
Actual
Start
Aug 8, 2019
Primary completion
Jul 8, 2026
Study completion Jul 8, 2026
Sponsor
- Lead sponsor
- Hospital Israelita Albert EinsteinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, Brazil
- First posted
- Aug 1, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
High blood pressure (BP) is a major public health concern, especially in low and middle income countries. High BP is a highly prevalent condition, and it is usually associated with diabetes mellitus. Both high BP and diabetes are risk factors for major cardiovascular events including cardiovascular death, acute myocardial infarction, stroke, unstable angina and heart failure. In addition, high BP is also related to cognitive decline. The OPTIMAL-DIABETES trial consists of a two-arm, multicenter, randomized clinical trial designed to test whether a lower systolic blood pressure (SBP) target will reduce the occurrence of major cardiovascular events in diabetic patients compared to the standard SBP target.
Conditions
- Diabetes Mellitus
- High Blood Pressure
- Cardiovascular Diseases
- Cognitive Impairment
Interventions
Intensive Control of Systolic Blood Pressure (SBP)Drug
Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
Standard control of Systolic Blood Pressure (SBP)Drug
The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failureTime frame: From randomization to 48 months
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Centro de Pesquisas Clínicas Dr Marco Mota
Maceió, Alagoas, Brazil
Centro de Pesquisas em Diabetes e Doenças Endocrino-Metabólicas
Fortaleza, Ceará, Brazil
Instituto de Estudos E Pesquisas Clinicas Do Ceara
Fortaleza, Ceará, Brazil
Hospital Universitário Cassiano Antonio de Moraes
Vitória, Espírito Santo, Brazil
Hospital Ana Nery
Salvador, Estado de Bahia, Brazil
Instituto Hospital de Base
Brasília, Federal District, Brazil
Universidade Federal de Goiás
Goiânia, Goiás, Brazil
NS Clínica de Diabetes e Endocrinologia Ltda
Goiânia, Goiás, Brazil
Hospital das Clinicas da Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil
Centro de Pesquisa do Hospital Santa Lúcia
Poços de Caldas, Minas Gerais, Brazil
Hospital Universitário João de Barros Barreto - UFPA
Belém, Pará, Brazil
Medicina Nuclear Alto da XV
Curitiba, Paraná, Brazil
Pronto Socorro Cardiológico de Pernambuco Prof. Luiz Tavares da Silva
Recife, Pernambuco, Brazil
Faculdade de Ciências Médicas - Universidade do Estado do Rio de Janeiro
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Endocrinologia Geloneze
Campinas, São Paulo, Brazil
Universidade Estadual de Campinas - UNICAMP
Campinas, São Paulo, Brazil
Indacor Servicos Medicos Ltda
Indaiatuba, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Ribeirão Preto, São Paulo, Brazil
Centro Integrado de Pesquisas
São José do Rio Preto, São Paulo, Brazil
Clínica Vilela & Martin
São José do Rio Preto, São Paulo, Brazil
Instituto de Cardiologia e Endocrinologia Rio Preto Ltda
São José do Rio Preto, São Paulo, Brazil
Clínica de Metabologia e Hipertensão da Universidade Federal de São Paulo
São Paulo, São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, São Paulo, Brazil
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, São Paulo, Brazil
Instituto Dante Pazzanese de Cardiologia
São Paulo, São Paulo, Brazil
Irmandade Da Santa Casa de Misericordia de Sao Paulo
São Paulo, São Paulo, Brazil
Real e Benemérita Associação Portuguesa de Beneficência/SP
São Paulo, São Paulo, Brazil
Clínica Cardiológica
Votuporanga, São Paulo, Brazil
Santa Casa de Misericordia de Votuporanga
Votuporanga, São Paulo, Brazil
Centro de Pesquisa Clínica do Coração
Aracaju, Sergipe, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.